Search by drug, manufacturer, or indication

Displaying 1051 - 1060 of 1165

Constella (linaclotide)

Status:

Negotiations were not pursued

Manufacturer:

Forest Laboratories Canada

Indication:

Irritable bowel syndrome with constipation

Last updated November 2, 2015

Xalkori (crizotinib)

Status:

Concluded with an LOI

Manufacturer:

Pfizer Canada ULC

Indication:

Non-Small Cell Lung Cancer (First Line)

Last updated October 8, 2015

Fibristal (ulipristal acetate)

Status:

Concluded with an LOI

Manufacturer:

Allergan Inc.

Indication:

Uterine fibroids (signs and symptoms)

Last updated September 18, 2015

Istodax (romidepsin)

Status:

Concluded with an LOI

Manufacturer:

Celgene Inc.

Indication:

Peripheral T-cell Lymphoma (PTCL)

Last updated September 16, 2015

Aptiom (eslicarbazepine acetate)

Status:

Concluded with an LOI

Manufacturer:

Sunovion Pharmaceuticals Canada Inc.

Indication:

Epilepsy, partial-onset seizures

Last updated September 8, 2015

Stivarga (regorafenib)

Status:

Negotiations were not pursued

Manufacturer:

Bayer Inc.

Indication:

Metastatic Colorectal Cancer

Last updated August 31, 2015

Firazyr (icatibant)

Status:

Concluded with an LOI

Manufacturer:

Shire Pharma Canada ULC

Indication:

Hereditary Angioedema

Last updated August 28, 2015

Simbrinza (brinzolamide/brimonidine)

Status:

Concluded with an LOI

Manufacturer:

Alcon Canada Inc.

Indication:

Glaucoma and Ocular Hypertension

Last updated August 27, 2015

Perjeta/Herceptin (pertuzumab/trastuzumab)

Status:

Negotiations were not pursued

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Neoadjuvant Breast Cancer

Last updated July 29, 2015

Nexavar (sorafenib)

Status:

Negotiations were not pursued

Manufacturer:

Bayer Inc.

Indication:

Metastatic Progressive Differentiated Thyroid Carcinoma

Last updated July 29, 2015